Epileptogenic potential of carbapenem agents: Mechanism of action, seizure rates, and clinical considerations

Pharmacotherapy

Volumn 31, Issue 4, 2011, Pages 408-423

  Miller, April D ^a   Ball, Amanda M ^b   Bookstaver, P Brandon ^a   Dornblaser, Emily K ^c   Bennett, Charles L ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF NEW ENGLAND   (United States)

Author keywords

Carbapenem; Central nervous system toxicity; Doripenem; Epilepsy; Ertapenem; Imipenem; Meropenem; Seizure

Indexed keywords

ANTIINFECTIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BIAPENEM; CARBAPENEM; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CYCLOSPORIN; DIAZEPAM; DORIPENEM; ERTAPENEM; LEVOFLOXACIN; LORAZEPAM; MEROPENEM; METRONIDAZOLE; MIDAZOLAM; PANIPENEM PLUS BETAMIPRON; PHENYTOIN; PIPERACILLIN PLUS TAZOBACTAM; PROBENECID; TEBIPENEM; THEOPHYLLINE DERIVATIVE; TOMOPENEM; VALPROIC ACID; VANCOMYCIN;

ABDOMINAL INFECTION; AREA UNDER THE CURVE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONTINUOUS INFUSION; CONVULSION; CREATININE CLEARANCE; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EPILEPSY; EPILEPTIC STATE; EPILEPTOGENESIS; EXPERIMENTAL THERAPY; FEBRILE NEUTROPENIA; GABAERGIC TRANSMISSION; GRAND MAL SEIZURE; HEMODIALYSIS; HOSPITAL INFECTION; HUMAN; LOW DRUG DOSE; MENINGITIS; NONHUMAN; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SEIZURE; SEPSIS; SINGLE DRUG DOSE; SKIN INFECTION; SOFT TISSUE INFECTION; UNITED STATES; URINARY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTICONVULSANTS; CARBAPENEMS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; SEIZURES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79953736060     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.4.408     Document Type: Review

References (127)

1. Johnson H, Walker A. Intraventricular penicillin: a note of warning. JAMA 1945;32:190-4.
2. Boston Collaborative Drug Surveillance Program. Drug-induced convulsions: report from the Boston collaborative drug surveillance program. Lancet 1972;2:677-9.
3. Calandra G, Lydick E, Carrigan J, Weiss L, Guess H. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem-cilastatin. Am J Med 1988;84:911-18.
4. Wallace KL. Antibiotic-induced convulsions. Crit Care Clin 1997;13:741-62. (Pubitemid 27432891)
5. Chow KM, Szeto CC, Hui AC, Wong TY, Li PK. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy 2003;23:369-73. (Pubitemid 36259341)
6. Merck & Co., Inc. Primaxin (imipenem-cilastatin) package insert. Whitehouse Station, NJ; 2010.
7. Calandra GB, Brown KR, Grad LC, Ahonkhai VI, Wang C, Aziz MA. Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem-cilastatin. Am J Med 1985;78:73-8. (Pubitemid 15073707)
8. Calandra GB, Ricci FM, Wang C, Brown KR. The efficacy results and safety profile of imipenem-cilastatin from the clinical research trials. J Clin Pharmacol 1988;28:120-7.
9. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005-2009. Epilepsia 2009;51:676-85.
10. Merriam-Webster. Merriam-Webster's medical dictionary. Available from www.merriam-webster.com/medical. Accessed September 20, 2010.
11. Wieser HG. Limbic status epilepticus (psychomotor status). Available from www.ilae-epilepsy.org/visitors/centre/ctf/psychomotor-status.cfm. Accessed September 20, 2010.
12. Chow KM, Hui AC, Szeto CC. Neurotoxicity induced by β-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis 2005;24:649-53. (Pubitemid 41670564)
13. De Sarro A, De Sarro GB, Ascioti C, Nistico G. Epileptogenic activity of some β-lactam derivatives: structure-activity relationship. Neuropharmacology 1989;28:359-65. (Pubitemid 19108794)
14. Williams PD, Bennett DB, Comereski CR. Animal model for evaluating the convulsive liability of β-lactam antibiotics. Antimicrob Agents Chemother 1988;32:758-60.
15. De Sarro G, Ammendola D, Nava F, De Sarro A. Effects of some excitatory amino acid antagonists on imipenem-induced seizures in DBA/2 mice. Brain Res 1995;671:131-40.
16. Antoniadis A, Muller WE, Wollert U. Inhibition of GABA and benzodiazepine receptor binding by penicillins. Neurosci Lett 1980;18:309-12. (Pubitemid 10090775)
17. Sunagawa M, Matsumura H, Sumita Y, Nouda H. Structural features resulting in convulsive activity of carbapenem compounds: effect of C-2 side chain. J Antibiot (Tokyo) 1995;48:408-16.
18. Merck & Co., Inc. Invanz (ertapenem) package insert. Whitehouse Station, NJ; 2010.
19. Zhanel GG, Ketter N, Redman R, Lee M, Rubinstein E, Friedland I. Doripenem: a carbapenem with low seizure-inducing potential [abstract]. Presented at the 48th annual ICAAC/IDSA 46th annual meeting: a joint meeting of the American Society for Microbiology and the Infectious Diseases Society of America, Washington, DC, October 25-28, 2008.
20. Norrby SR. Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis. J Antimicrob Chemother 2000;45:5-7. (Pubitemid 30060227)
21. Hoffman J, Trimble J, Brophy GM. Safety of imipenemcilastatin in neurocritical care patients. Neurocrit Care 2009;10:403-7.
22. Calandra GB, Wang C, Aziz M, Brown KR. The safety profile of imipenem-cilastatin: worldwide clinical experience based on 3470 patients. J Antimicrob Chemother 1986;18(suppl E):193-202. (Pubitemid 17212645)
23. Bodey G, Abi-Said D, Rolston K, Raad I, Whimbey E. Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients. Eur J Clin Microbiol Infect Dis 1996;15:625-34. (Pubitemid 26326751)
24. Wong VK, Wright HT Jr, Ross LA, Mason WH, Inderlied CB, Kim KS. Imipenem-cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991;10:122-5.
25. Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RE. Controlled trials of double β-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients. Am J Med 1988;85:21-30.
26. Winston DJ, Bartoni K, Bruckner DA, Schiller GJ, Territo MC. Randomized comparison of sulbactam-cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis 1998;26:576-83. (Pubitemid 28155002)
27. Winston DJ, Ho WG, Bruckner DA, Champlin RE. β-lactam antibiotic therapy in febrile granulocytopenic patients: a randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 1991;115:849-59.
28. Rolston KV, Berkey P, Bodey GP, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992;152:283-91.
29. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995;13:165-76.
30. Aparicio J, Oltra A, Llorca C, et al. Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients. Eur J Cancer 1996;32A:1739-43. (Pubitemid 26306886)
31. Raad II, Whimbey EE, Rolston KV, et al. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients. Cancer 1996;77:1386-94. (Pubitemid 26102341)
32. Winston DJ, Lazarus HM, Beveridge RA, et al. Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis 2001;32:381-90. (Pubitemid 32173623)
33. Raad II, Escalante C, Hachem RY, et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime. Cancer 2003;98:1039-47. (Pubitemid 37022106)
34. Schmitt DV, Leitner E, Welte T, Lode H. Piperacillin-tazobactam vs imipenem-cilastatin in the treatment of nosocomial pneumonia: a double-blind prospective multicentre study. Infection 2006;34:127-34. (Pubitemid 43979660)
35. Fink MP, Snydman DR, Niederman MS, et al, for the Severe Pneumonia Study Group. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994;38:547-57.
36. Hamacher J, Vogel F, Lichey J, et al, for the COPD Study Group. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients: a comparison of meropenem and imipenem-cilastatin. J Antimicrob Chemother 1995;36(suppl A):121-33.
37. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008;36:1089-96. (Pubitemid 351482655)
38. Rodloff AC, Goldstein EJ, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother 2006;58:916-29.
39. Merchant MR, Anwar N, Were A, Uttley L, Tooth JA, Gokal R. Imipenem versus netilmicin and vancomycin in the treatment of CAPD peritonitis. Adv Perit Dial 1992;8:234-37.
40. Anwar N, Merchant M, Were T, Tooth A, Uttley L, Gokal R. A prospective, randomized study of the comparative safety and efficacy of intraperitoneal imipenem versus vancomycin and netilmicin in the treatment of peritonitis on CAPD. Perit Dial Int 1995;15:167-71.
41. Solomkin JS, Dellinger EP, Christou NV, Busuttil RW. Results of a multicenter trial comparing imipenem-cilastatin to tobramycin-clindamycin for intra-abdominal infections. Ann Surg 1990;212:581-91.
42. Brismar B, Malmborg AS, Tunevall G, et al. Meropenem versus imipenem-cilastatin in the treatment of intra-abdominal infections. J Antimicrob Chemother 1995;35:139-48.
43. Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin-sulbactam versus imipenem-cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1994;18:683-93. (Pubitemid 24145900)
44. Lode H, Wiley R, Hoffken G, Wagner J, Borner K. Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections. Antimicrob Agents Chemother 1987;31:1491-6.
45. Norrby SR, Finch RG, Glauser M, for the European Study Group. Monotherapy in serious hospital-acquired infections: a clinical trial of ceftazidime versus imipenem-cilastatin. J Antimicrob Chemother 1993;31:927-37. (Pubitemid 23218155)
46. Gonik B. Postpartum endometritis: efficacy and tolerability of two antibiotic regimens. Clin Ther 1992;14:83-9.
47. Cometta A, Baumgartner JD, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994;38:1309-13. (Pubitemid 24170712)
48. Garau J, Blanquer J, Cobo L, et al. Prospective, randomised, multicentre study of meropenem versus imipenem-cilastatin as empiric monotherapy in severe nosocomial infections. Eur J Clin Microbiol Infect Dis 1997;16:789-96. (Pubitemid 27527055)
49. Jaccard C, Troillet N, Harbarth S, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998;42:2966-72. (Pubitemid 28501234)
50. Marra F, Reynolds R, Stiver G, et al. Piperacillin-tazobactam versus imipenem: a double-blind, randomized formulary feasibility study at a major teaching hospital. Diagn Microbiol Infect Dis 1998;31:355-68. (Pubitemid 28255136)
51. Simpson AJ, Suputtamongkol Y, Smith MD, et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin Infect Dis 1999;29:381-7. (Pubitemid 29380204)
52. Kuo BI, Fung CP, Liu CY. Meropenem versus imipenem-cilastatin in the treatment of sepsis in Chinese patients. Zhonghua Yi Xue Za Zhi (Taipei) 2000;63:361-7. (Pubitemid 30390047)
53. Verwaest C. Meropenem versus imipenem-cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clin Microbiol Infect 2000;6:294-302. (Pubitemid 34960221)
54. Solomkin JS, Fant WK, Rivera JO, Alexander JW. Randomized trial of imipenem-cilastatin versus gentamicin and clindamycin in mixed flora infections. Am J Med 1985;78:85-91. (Pubitemid 15073709)
55. Lode H, Wiley E, Olschewski P, et al. Prospective randomized clinical trials of new quinolones versus β-lactam antibiotics in lower respiratory tract infections. Scand J Infect Dis Suppl 1990;68:50-5. (Pubitemid 20259265)
56. Brotherton TJ, Kelber RL. Seizure-like activity associated with imipenem. Clin Pharm 1984;3:536-40. (Pubitemid 14030991)
57. Tse CS, Hernandez Vera F, Desai DV. Seizure-like activity associated with imipenem-cilastatin. Drug Intell Clin Pharm 1987;21:659-60. (Pubitemid 17098380)
58. Eng RH, Munsif AN, Yangco BG, Smith SM, Chmel H. Seizure propensity with imipenem. Arch Intern Med 1989;149:1881-3. (Pubitemid 19200849)
59. Job ML, Dretler RH. Seizure activity with imipenem therapy: incidence and risk factors. DICP 1990;24:467-9. (Pubitemid 20149722)
60. Bosmuller C, Steurer W, Konigsrainer A, Willeit J, Margreiter R. Increased risk of central nervous system toxicity in patients treated with ciclosporin and imipenem-cilastatin. Nephron 1991;58:362-4.
61. Semel JD, Allen N. Seizures in patients simultaneously receiving theophylline and imipenem or ciprofloxacin or metronidazole. South Med J 1991;84:465-8.
62. Leo RJ, Ballow CH. Seizure activity associated with imipenem use: clinical case reports and review of the literature. DICP 1991;25:351-4.
63. Hunter WJ. Imipenem-induced seizure: a case of inappropriate, excessive, and prolonged surgical prophylaxis. Hosp Pharm 1993;28:986-8. (Pubitemid 23318139)
64. Lane M, Kania D, Rapp RP. Seizures related to use of imipenem-cilastatin. Am J Health Syst Pharm 1996;53:1605-6.
65. Campise M. Neurological complication during imipenem-cilastatin therapy in uraemic patients. Nephrol Dial Transplantl 1998;13:1895-6. (Pubitemid 28306848)
66. Rivera M, Crespo M, Teruel JL, Marcen R, Ortuno J. Neurotoxicity due to imipenem-cilastatin in patients on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1999;14:258-9. (Pubitemid 29041929)
67. Fernandez-Torre JL, Velasco M, Gutierrez R, Fernandez-Sampedro M. Encephalopathy secondary to imipenem therapy. Clin EEG Neurosci 2004;35:100-3. (Pubitemid 38623643)
68. Lamoth F, Erard V, Asner S, Buclin T, Calandra T, Marchetti O. High imipenem blood concentrations associated with toxic encephalopathy in a patient with mild renal dysfunction. Int J Antimicrob Agents 2009;34:386-8.
69. Galante D. An unusual cause of seizures during subarachnoid anesthesia in a patient undergoing transurethral resection of the prostate: a case report. Minerva Anestesiol 2009;75:221-3.
70. Nichols RL, Smith JW, Geckler RW, Wilson SE. Meropenem versus imipenem-cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J 1995;88:397-404.
71. Fabian TC, File TM, Embil JM, et al. Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. Surg Infect (Larchmt) 2005;6:269-82. (Pubitemid 41645593)
72. AstraZeneca. Merrem (meropenem) package insert. Wilmington, DE; 2009.
73. Norrby SR, Newell PA, Faulkner KL, Lesky W. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995;36(suppl A):207-23.
74. Linden P. Safety profile of meropenem: an updated review of over 6000 patients treated with meropenem. Drug Saf 2007;30:657-68. (Pubitemid 47295825)
75. Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5000 patients treated with meropenem. Scand J Infect Dis 1999;31:3-10. (Pubitemid 29253570)
76. Klugman KP, Dagan R, for the Meropenem Meningitis Study Group. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Antimicrob Agents Chemother 1995;39:1140-6.
77. Hsu HL, Lu CY, Tseng HY, et al. Empirical monotherapy with meropenem in serious bacterial infections in children. J Microbiol Immunol Infect 2001;34:275-80.
78. Odio CM, Puig JR, Feris JM, et al, for the Meropenem Meningitis Study Group. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs cefotaxime therapy in bacterial meningitis in children. Pediatr Infect Dis J 1999;18:581-90.
79. Baraboutis IG, Marangos MN, Skoutelis A, Bassaris H. Meropenem-aggravated seizure activity in progressive myoclonus epilepsy. Int J Antimicrob Agents 2008;31:177-9.
80. Ortho-McNeil-Janssen. Doribax (doripenem) package insert. Raritan, NJ; 2007.
81. Paterson DL, Depestel DD. Doripenem. Clin Infect Dis 2009;49:291-8.
82. Horiuchi M, Kimura M, Tokumura M, Hasebe N, Arai T, Abe K. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with β-lactam antibiotics. Toxicology 2006;222:114-24. (Pubitemid 44275125)
83. Redman R, File TM Jr. Safety of intravenous infusion of doripenem. Clin Infect Dis 2009;49(suppl 1):S28-35.
84. Naber KG, Llorens L, Kaniga K, Kotey P, Hedrich D, Redman R. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother 2009;53:3782-92.
85. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008;30:868-83. (Pubitemid 351799866)
86. Rea-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin-tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008;24:2113-26.
87. Zhanel GG, Ketter N, Rubinstein E, Friedland I, Redman R. Overview of seizure-inducing potential of doripenem. Drug Saf 2009;32:709-16.
88. Majumdar AK, Musson DG, Birk KL, et al. Pharmacokinetics of ertapenem in healthy young volunteers. Antimicrob Agents Chemother 2002;46:3506-11. (Pubitemid 35192918)
89. Cottagnoud P, Pfister M, Cottagnoud M, Acosta F, Tauber MG. Activities of ertapenem, a new long-acting carbapenem, against penicillin-sensitive or -resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2003;47:1943-7. (Pubitemid 36637818)
90. Teppler H, Gesser RM, Friedland IR, et al. Safety and tolerability of ertapenem. J Antimicrob Chemother 2004;53(suppl 2):ii75-81.
91. Roy S, Higareda I, Angel-Muller E, et al. Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study. Infect Dis Obstet Gynecol 2003;11:27-37. (Pubitemid 36604819)
92. Solomkin JS, Yellin AE, Rotstein OD, et al. Ertapenem versus piperacillin-tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 2003;237:235-45. (Pubitemid 38173251)
93. Navarro NS Jr, Campos MI, Alvarado R, et al. Ertapenem versus ceftriaxone and metronidazole as treatment for complicated intra-abdominal infections. Int J Surg 2005;3:25-34. (Pubitemid 41095565)
94. Dela Pena AS, Asperger W, Kockerling F, et al. Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention. J Gastrointest Surg 2006;10:567-74. (Pubitemid 44313807)
95. Namias N, Solomkin JS, Jensen EH, Tomassini JE, Abramson MA. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults. Surg Infect (Larchmt) 2007;8:15-28. (Pubitemid 46598292)
96. Legua P, Lema J, Moll J, Jiang Q, Woods G, Friedland I. Safety and local tolerability of intramuscularly administered ertapenem diluted in lidocaine: a prospective, randomized, double-blind study versus intramuscular ceftriaxone. Clin Ther 2002;24:434-44. (Pubitemid 34275864)
97. Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, Woods GL, Carides A. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis 2002;34:1076-83. (Pubitemid 34289680)
98. Vetter N, Cambronero-Hernandez E, Rohlf J, et al. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin Ther 2002;24:1770-85. (Pubitemid 35440949)
99. Jimenez-Cruz F, Jasovich A, Cajigas J, et al. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urologyl 2002;60:16-22. (Pubitemid 34722938)
100. Tomera KM, Burdmann EA, Reyna OG, et al. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study. Antimicrob Agents Chemother 2002;46:2895-900.
101. Graham DR, Lucasti C, Malafaia O, et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis 2002;34:1460-8. (Pubitemid 34553705)
102. Lipsky BA, Armstrong DG, Citron DM, Tice AD, Morgenstern DE, Abramson MA. Ertapenem versus piperacillin-tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 2005;366:1695-703. (Pubitemid 41587448)
103. Yakovlev SV, Stratchounski LS, Woods GL, et al. Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit. Eur J Clin Microbiol Infect Dis 2006;25:633-41. (Pubitemid 44526876)
104. Basoli A, Chirletti P, Cirino E, et al. A prospective, double-blind, multicenter, randomized trial comparing ertapenem 3 vs ≥ 5 days in community-acquired intraabdominal infection. J Gastrointest Surg 2008;12:592-600.
105. Boselli E, Breilh D, Saux MC, Gordien JB, Allaouchiche B. Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia. Intensive Care Med 2006;32:2059-62. (Pubitemid 44833122)
106. Burkhardt O, Kumar V, Katterwe D, et al. Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother 2007;59:277-84. (Pubitemid 47072067)
107. Seto AH, Song JC, Guest SS. Ertapenem-associated seizures in a peritoneal dialysis patient. Ann Pharmacother 2005;39:352-6. (Pubitemid 40165228)
108. Saidel-Odes L, Borer A, Riesenberg K, Smolyakov R, Schlaeffer F. History of cerebrovascular events: a relative contraindication to ertapenem treatment. Clin Infect Dis 2006;43:262-3.
109. Lunde JL, Nelson RE, Storandt HF. Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy. Pharmacotherapy 2007;27:1202-5. (Pubitemid 47173664)
110. Fica AE, Abusada NJ. Seizures associated with ertapenem use in patients with CNS disorders and renal insufficiency. Scand J Infect Dis 2008;40:983-5.
111. Ong C, Chua AC, Tambyah PA, Fei YS. Seizures associated with ertapenem [case report]. Int J Antimicrob Agents 2008;31:290. (Pubitemid 351232172)
112. Kofke WA. Anesthetic management of the patient with epilepsy or prior seizures. Curr Opin Anaesthesiol 2010;23:391-9.
113. Woods GL, Isaacs RD, McCarroll KA, Friedland IR. Ertapenem therapy for community-acquired pneumonia in the elderly. J Am Geriatr Soc 2003;51:1526-32. (Pubitemid 37409585)
114. Musson DG, Majumdar A, Holland S, et al. Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects. Antimicrob Agents Chemother 2004;48:521-4. (Pubitemid 38141711)
115. Nix DE, Majumdar AK, DiNubile MJ. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother 2004;53(suppl 2):ii23-8.
116. Katsuki K, Shinohara K, Yamada T. A case of fatal seizure and unconsciousness caused by panipenem-betamipron. Kansenshogaku Zasshi 1998;72:651-3.
117. Perry CM, Ibbotson T. Biapenem. Drugs 2002;62:2221-35.
118. Yagi Y, Nawa T, Kurata Y, Shibasaki S, Suzuki H, Kurosawa T. Convulsive liability of an oral carbapenem antibiotic, tebipenem pivoxil. Jpn J Antibiot 2009;62:241-52.
119. Mallalieu NL, Lennon S, Liu M, et al. Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem. Antimicrob Agents Chemother 2008;52:2360-6. (Pubitemid 351915663)
120. Gettig JP, Crank CW, Philbrick AH. Faropenem medoxomil. Ann Pharmacother 2008;42:80-90.
121. Sunagawa M, Matsumura H, Inoue T, Fukasawa M. New penem compounds with 5′-substituted pyrrolidinylthio group as a C-2 side chain: comparison of their biological properties with those of carbapenem compounds. J Antibiot (Tokyo) 1992;45:500-4.
122. El-Bitar MK, Boustany RM. Common causes of uncommon seizures. Pediatr Neurol 2009;41:83-7.
123. Mancl EE, Gidal BE. The effect of carbapenem antibiotics on plasma concentrations of valproic acid. Ann Pharmacother 2009;43:2082-7.
124. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006;61:246-55. (Pubitemid 43382623)
125. Tobin JK, Golightly LK, Kick SD, Jones MA. Valproic acid-carbapenem interaction: report of six cases and a review of the literature. Drug Metab Drug Interact 2009;24:153-82.
126. Mori H, Takahashi K, Mizutani T. Interaction between valproic acid and carbapenem antibiotics. Drug Metab Rev 2007;39:647-57. (Pubitemid 350208726)
127. Nakajima Y, Mizobuchi M, Nakamura M, et al. Mechanism of the drug interaction between valproic acid and carbapenem antibiotics in monkeys and rats. Drug Metab Dispos 2004;32:1383-91. (Pubitemid 39564558)